Valuation: SpectraCure AB

Market Cap 3.64Cr 37.75L 33L 30.32L 28.27L 53.61L 36Cr 54.42L 1.42Cr 18Cr 1.42Cr 1.39Cr 61Cr P/E 2024
-10.6x
P/E 2025 -0.79x
Enterprise Value 2.57Cr 26.61L 23.27L 21.38L 19.93L 37.8L 25Cr 38.37L 99.79L 12Cr 99.9L 97.75L 43Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.17%
Yield 2024 *
-
Yield 2025 -
1 day+0.31%
1 week+24.27%
Current month+16.36%
1 month-50.54%
3 months-23.44%
6 months-54.29%
Current year-58.92%
1 week 0.04
Extreme 0.0441
0.08
1 month 0.04
Extreme 0.0403
0.14
Current year 0.04
Extreme 0.0403
0.17
1 year 0.04
Extreme 0.0403
0.32
3 years 0.04
Extreme 0.0403
6.4
5 years 0.04
Extreme 0.0403
13.19
10 years 0.04
Extreme 0.0403
45.15
Manager TitleAgeSince
Chief Executive Officer 54 01/10/2025
Director of Finance/CFO - 01/06/2026
Chief Tech/Sci/R&D Officer - 07/10/2025
Director TitleAgeSince
Director/Board Member 63 31/08/2012
Director/Board Member 72 01/01/2022
Chairman 74 01/01/2022
Date Insider Type Main position Quantity % Market Cap.
26/23/26Buy

Chairman

25,000 0.0257%
30/22/30Buy

Director

25,000 0.0257%
09/22/09Buy

Director

10,48,493 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
+0.31%+24.27%-74.09%-98.97% 37.75L
-1.77%+0.12%+51.28%+58.25% 160.26Cr
+0.76%-0.75%-41.15%-48.65% 30Cr
-1.34%+1.38%-9.87%-49.77% 5.44Cr
+3.85%+12.50%+28.57%-6.90% 5.41Cr
Average +0.36%+12.88%-9.05%-29.21% 40.21Cr
Weighted average by Cap. -1.23%+2.03%+35.18%+37.56%

Financials

2024 2025
Net sales - -
Net income -2.3Cr -23.85L -20.85L -19.16L -17.86L -33.88L -23Cr -34.39L -89.43L -11Cr -89.53L -87.61L -38Cr -5.61Cr -58.14L -50.83L -46.71L -43.54L -82.59L -55Cr -83.84L -2.18Cr -27Cr -2.18Cr -2.14Cr -94Cr
Net Debt -1.31Cr -13.61L -11.9L -10.94L -10.19L -19.33L -13Cr -19.63L -51.04L -6.37Cr -51.1L -50L -22Cr -1.07Cr -11.13L -10L -9L -8L -15.81L -11Cr -16.05L -41.74L -5.21Cr -41.78L -40.89L -18Cr
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
06/26/06 SEK 0.0640 +0.31% 12,14,291
03/26/03 SEK 0.0638 +10.38% 31,79,269
02/26/02 SEK 0.0578 +1.58% 17,46,018
01/26/01 SEK 0.0569 +3.45% 9,65,330
30/26/30 SEK 0.0550 +6.80% 84,28,686
  1. Stock Market
  2. Stocks
  3. SPEC Stock